Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on immune cells to suppress anti-tumor immune responses. In the past decade, antibodies targeting PD-1/PD...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1228200/full |
| _version_ | 1797798388023951360 |
|---|---|
| author | Yao Jiang Yao Jiang Kai Hong Yingchao Zhao Yingchao Zhao Kai Xu |
| author_facet | Yao Jiang Yao Jiang Kai Hong Yingchao Zhao Yingchao Zhao Kai Xu |
| author_sort | Yao Jiang |
| collection | DOAJ |
| description | Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on immune cells to suppress anti-tumor immune responses. In the past decade, antibodies targeting PD-1/PD-L1 have tremendously altered cancer treatment paradigms. Post-translational modifications have been reported as key regulators of PD-L1 expression. Among these modifications, ubiquitination and deubiquitination are reversible processes that dynamically control protein degradation and stabilization. Deubiquitinating enzymes (DUBs) are responsible for deubiquitination and have emerged as crucial players in tumor growth, progression, and immune evasion. Recently, studies have highlighted the participation of DUBs in deubiquitinating PD-L1 and modulating its expression. Here, we review the recent developments in deubiquitination modifications of PD-L1 and focus on the underlying mechanisms and effects on anti-tumor immunity. |
| first_indexed | 2024-03-13T04:03:54Z |
| format | Article |
| id | doaj.art-1e9fbdec22b2474f9d5daee43c5cf2c0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T04:03:54Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1e9fbdec22b2474f9d5daee43c5cf2c02023-06-21T09:56:01ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-06-011410.3389/fimmu.2023.12282001228200Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapyYao Jiang0Yao Jiang1Kai Hong2Yingchao Zhao3Yingchao Zhao4Kai Xu5Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaInstitute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on immune cells to suppress anti-tumor immune responses. In the past decade, antibodies targeting PD-1/PD-L1 have tremendously altered cancer treatment paradigms. Post-translational modifications have been reported as key regulators of PD-L1 expression. Among these modifications, ubiquitination and deubiquitination are reversible processes that dynamically control protein degradation and stabilization. Deubiquitinating enzymes (DUBs) are responsible for deubiquitination and have emerged as crucial players in tumor growth, progression, and immune evasion. Recently, studies have highlighted the participation of DUBs in deubiquitinating PD-L1 and modulating its expression. Here, we review the recent developments in deubiquitination modifications of PD-L1 and focus on the underlying mechanisms and effects on anti-tumor immunity.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1228200/fulldeubiquitinating enzymesdeubiquitinationcancer immunotherapypost-translational modificationprogrammed death-ligand-1 (PD-L1) |
| spellingShingle | Yao Jiang Yao Jiang Kai Hong Yingchao Zhao Yingchao Zhao Kai Xu Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy Frontiers in Immunology deubiquitinating enzymes deubiquitination cancer immunotherapy post-translational modification programmed death-ligand-1 (PD-L1) |
| title | Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy |
| title_full | Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy |
| title_fullStr | Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy |
| title_full_unstemmed | Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy |
| title_short | Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy |
| title_sort | emerging role of deubiquitination modifications of programmed death ligand 1 in cancer immunotherapy |
| topic | deubiquitinating enzymes deubiquitination cancer immunotherapy post-translational modification programmed death-ligand-1 (PD-L1) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1228200/full |
| work_keys_str_mv | AT yaojiang emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy AT yaojiang emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy AT kaihong emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy AT yingchaozhao emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy AT yingchaozhao emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy AT kaixu emergingroleofdeubiquitinationmodificationsofprogrammeddeathligand1incancerimmunotherapy |